A new report by research and consulting firm GlobalData has underscored the extreme blockbuster potential of non-alcoholic steatohepatitis (NASH).
Looking at the seven major markets (7MM) of the U.S., France, Germany, Italy, Spain, the U.K., and Japan, the authors determined that the field would expand at a compound annual growth rate (CAGR) of 45 percent.
